Development of a novel histone deacetylase inhibitor unveils the role of HDAC11 in alleviating depression by inhibition of microglial activation

Authors
Soo Yeon BaekHee, Lee JeeKim, TaegwanLee, HyelimChoi, Hoon-SeongPark, HahnbeomKoh, MinseobKim, EunhaJung, Michael E.Iliopoulos, DimitriosLee, Jeong-YeonKim, JonghoonLee, Sang hee
Issue Date
2023-10
Publisher
Elsevier Masson
Citation
Biomedicine & Pharmacotherapy, v.166
Abstract
Histone deacetylases (HDACs) are key epigenetic regulators and classified into four subtypes. Despite the various roles of each HDAC isoform, the lack of selective HDAC inhibitors has limited the elucidation of their roles in biological systems. HDAC11, the sole class-IV HDAC, is highly expressed in the brain, however, the role of HDAC11 in microglia is not fully understood. Based on the modification of MC1568, we developed a novel HDAC inhibitor, 5. Interestingly, 5 suppresses lipopolysaccharide-induced microglial activation by the initiation of autophagy and subsequent inhibition of nitric oxide production. Furthermore, we demonstrated that 5 significantly alleviates depression-like behavior by inhibiting microglial activation in mouse brain. Our discovery reveals that specific pharmacological regulation of HDAC11 induces autophagy and reactive nitrogen species balance in microglia for the first time, which makes HDAC11 a new therapeutic target for depressive disorder.
Keywords
HDAC inhibitor; Microglial activation; Neuroinflammation; Depressive disorder
ISSN
0753-3322
URI
https://pubs.kist.re.kr/handle/201004/79811
DOI
10.1016/j.biopha.2023.115312
Appears in Collections:
KIST Article > 2023
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE